Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 2,665 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: University of San Francisco Clear all
Completed Not applicable Interventional

Starzl Network Patient Reported Outcomes

NCT05241847
View directory record Official record
Conditions
Liver Transplant; Complications, Quality of Life, Child Behavior, Adolescent Behavior
Interventions
PeLTQL delivery via electronic means
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
8 Years to 20 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Oakland, California • Atlanta, Georgia • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 17, 2026, 11:42 AM EDT
Completed Not applicable Interventional

UCSF College Health Study on Contraceptive Training and Education at Community Colleges

NCT03519685
View directory record Official record
Conditions
Contraception
Interventions
Contraceptive Training and Education, Placebo Nutrition Education
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
2,086 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Oct 17, 2026, 11:42 AM EDT
Completed Phase 2 Interventional Results available

Anakinra as a Treatment for Hydradenitis Suppurativa

NCT01516749
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
anakinra
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Oct 17, 2026, 11:42 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

IMProving Adherence to Colonoscopy Through Teams and Technology

NCT06191185
View directory record Official record
Conditions
Colon Cancer, Cancer Colorectal, Colorectal Cancer
Interventions
BPB, No PIN, BPB, PIN, No BPB, PIN, No BPB, No PIN
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 17, 2026, 11:42 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases

NCT03457948
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Liver, Neuroendocrine Neoplasm
Interventions
Arterial Embolization, Pembrolizumab, Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate, Yttrium-90 Microsphere Radioembolization
Procedure · Biological · Device
Lead sponsor
Nicholas Fidelman, MD
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 17, 2026, 11:42 AM EDT
Terminated Phase 2 Interventional Results available

Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat

NCT03823131
View directory record Official record
Conditions
Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma
Interventions
ImmunoPulse, Epacadostat, Pembrolizumab, CORVax, Tavokinogene telseplasmid
Device · Drug · Biological
Lead sponsor
Chase Heaton, MD
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 17, 2026, 11:42 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Innate Immunity in Ozone-induced Airway Inflammation in COPD

NCT04669743
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Airway Disease, COPD Exacerbation, Pollution; Exposure, Pollution Related Respiratory Disorder
Interventions
Ozone exposure
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
45 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2030
U.S. locations
3
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 17, 2026, 11:42 AM EDT
Completed Phase 4 Interventional Results available

Mesalamine to Reduce T Cell Activation in HIV Infection

NCT01090102
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases, Immune System Diseases, Lentivirus Infections, Acquired Immunodeficiency Syndrome
Interventions
Mesalamine (5-aminosalicylic acid, Apriso), Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2014 · Synced Oct 17, 2026, 11:42 AM EDT
Completed Not applicable Interventional Results available

Lycopene or Omega-3 Fatty Acid Nutritional Supplements in Treating Patients With Stage I or Stage II Prostate Cancer

NCT00402285
View directory record Official record
Conditions
Prostate Cancer
Interventions
lycopene supplement, fish oil supplement, Placebo
Dietary Supplement · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
Male only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 1, 2016 · Synced Oct 17, 2026, 11:42 AM EDT
Terminated Not applicable Interventional Results available

Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma

NCT05273385
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension, Open Angle Glaucoma
Interventions
Nanodropper
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 17, 2026, 11:42 AM EDT
Recruiting Phase 3 Interventional

Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A

NCT06658002
View directory record Official record
Conditions
Fungal Keratitis, Corneal Ulcer
Interventions
Cyclosporine A, Placebo Comparator: Placebo
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 17, 2026, 11:42 AM EDT
Completed Phase 1 Interventional

Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors

NCT01670175
View directory record Official record
Conditions
Malignant Solid Tumor, Childhood Solid Tumor
Interventions
Sirolimus, Cyclophosphamide, Topotecan
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 25 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Oct 17, 2026, 11:42 AM EDT
Completed No phase listed Observational

Comparison of CT Angiography With Conventional Angiography and Intravascular Ultrasound in Heart Transplant Patients

NCT00723281
View directory record Official record
Conditions
Heart Transplantation, Coronary Artery Disease
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 99 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2019 · Synced Oct 17, 2026, 11:42 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Genomic Sequencing for Evaluation of Fetal Structural Anomalies

NCT06054230
View directory record Official record
Conditions
Fetal Structural Anomalies
Interventions
Genomic Sequencer
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 64 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 17, 2026, 11:42 AM EDT
Recruiting No phase listed Observational

Mechanisms of Resistance to PSMA Radioligand Therapy

NCT05435495
View directory record Official record
Conditions
Prostate Cancer
Interventions
Single-photon emission computed tomography, Blood Draw, Tumor Biopsy
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 17, 2026, 11:42 AM EDT
Active, not recruiting Not applicable Interventional

Guaranteed Income to Boost HIV Care Continuity and Suppression Post-Jail Release

NCT07115901
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus)
Interventions
Lump sum, Monthly installments, Choice
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 17, 2026, 11:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Hemangioma Growth During the First 6 Months of Life

NCT00911781
View directory record Official record
Conditions
Hemangiomas of Infancy
Interventions
No intervention
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
3 Months to 5 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
San Francisco, California • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Oct 17, 2026, 11:42 AM EDT
Completed Phase 1Phase 2 Interventional

Herbal Therapy in Treating Women With Metastatic Breast Cancer

NCT00028977
View directory record Official record
Conditions
Breast Cancer
Interventions
herba scutellaria barbata, herba scutellaria Barbatae (HSB)
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
2
States / cities
San Francisco, California • Plantation, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2012 · Synced Oct 17, 2026, 11:42 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Attitudes and Decision-making After Pregnancy Testing Study

NCT03888404
View directory record Official record
Conditions
Unintended Pregnancy, Undesired Pregnancy
Interventions
Pregnancy preferences (Aim 1), Sociocultural environment (Aim 2), Pregnancy preferences (Aim 3a), Pregnancy (Aim 3b)
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
15 Years to 34 Years · Female only
Enrollment
2,015 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 17, 2026, 11:42 AM EDT
Completed Not applicable Interventional Results available

Delish Study: Diabetes Education to Lower Insulin, Sugars, and Hunger

NCT03207711
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Carbohydrate-restricted diet, Mindfulness
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 17, 2026, 11:42 AM EDT
Completed No phase listed Observational

Study of Clofarabine and Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation (HCT)

NCT03609814
View directory record Official record
Conditions
Hematologic Malignancies, Nonmalignant Diseases, Immunodeficiencies, Hemoglobinopathies, Genetic Inborn Errors of Metabolism, Fanconi's Anemia, Thalassemia, Sickle Cell Disease
Interventions
Clofarabine, Fludarabine Injection
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Oct 17, 2026, 11:42 AM EDT
Recruiting Not applicable Interventional

Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers

NCT04221893
View directory record Official record
Conditions
Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Carcinoma, Stage IV Gastric Cancer, Stage IV Adenocarcinoma of the Gastroesophageal Junction, Stage IVA Esophageal Adenocarcinoma, Stage IVA Esophageal Squamous Cell Carcinoma, Stage IVA Gastric Cancer, Stage IVA Adenocarcinoma of the Gastroesophageal Junction, Stage IVB Esophageal Adenocarcinoma, Stage IVB Esophageal Squamous Cell Carcinoma, Stage IVB Gastric Cancer, Stage IVB Gastroesophageal Junction Adenocarcinoma, Metastatic Anal Canal Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Malignant Digestive System Neoplasm, Metastatic Small Intestinal Carcinoma, Pancreatobiliary Carcinoma, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC V8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Anal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Radiation Therapy (RT)
Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
San Francisco, California • Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 17, 2026, 11:42 AM EDT
Completed Not applicable Interventional

Peer Coaching for Low-Income Patients With Diabetes in Primary Care

NCT01040806
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Usual care, Health coaching
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 17, 2026, 11:42 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparing the Efficacy of Ultravate Ointment in Combination With Lac-Hydrin Lotion in the Treatment of Psoriasis

NCT00990561
View directory record Official record
Conditions
Stable Plaque Psoriasis
Interventions
Ultravate ointment twice daily + LacHydrin lotion twice daily, Ultravate ointment once daily + LacHydrin lotion twice daily
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Oct 17, 2026, 11:42 AM EDT